Considering the potential effects of polyunsaturated fatty acids (PUFAs) on AD, a study further revealed that peroral supplementation of omega-3 fatty acids can result in increasing the level of the cerebrospinal fluid biomarker Chi3l1 in patients with AD, indicating possible aggravation of the inflammatory response and axonal damage [162]. Here, CHI3L1 is linked to Alzheimer disease.